Menu Search
Equities

Quest Diagnostics Inc

QDI:BER

Quest Diagnostics Inc

Actions
  • Price (EUR)124.75
  • Today's Change-1.00 / -0.80%
  • Shares traded0.00
  • 1 Year change+19.95%
  • Beta--
Data delayed at least 15 minutes, as of Oct 22 2021 07:05 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates under two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services develops and delivers diagnostic testing information and services, providing insights that enables a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers, and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, and other brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, Quanum. It also helps in delivering diagnostic insights for COVID-19 and a range of other medical conditions for communities in South Florida.

  • Revenue in USD (TTM)11.05bn
  • Net income in USD2.18bn
  • Incorporated1996
  • Employees40.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		DGX:NYQ since
announced		Transaction
value
St Johns Mercy-Laboratory Services BusinessDeal completed08 Mar 202108 Mar 2021Deal completed23.23%--
Data delayed at least 15 minutes, as of Oct 21 2021 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.